Peptides for Insulin Resistance — Evidence Review
Insulin resistance precedes type 2 diabetes, drives PCOS metabolic features, contributes to MASLD (formerly NAFLD), and underlies metabolic syndrome. It's measurable (HOMA-IR, fasting insulin,…
Insulin resistance precedes type 2 diabetes, drives PCOS metabolic features, contributes to MASLD (formerly NAFLD), and underlies metabolic syndrome. It's measurable (HOMA-IR, fasting insulin, OGTT-derived indices) and modifiable.
The peptide class with the strongest insulin-sensitizing data is the incretin agonists. The MOTS-c story is intriguing but early.
Peptides with the strongest evidence
Semaglutide
Improves insulin sensitivity through multiple pathways: weight reduction (the dominant effect), enhanced glucose-dependent insulin secretion, and reduced postprandial hyperinsulinemia. The SUSTAIN trial program documented sustained HOMA-IR reductions tracking with weight loss. Mechanism differs from metformin (which acts primarily on hepatic glucose production) — these are complementary, not redundant, in mechanism.
Tirzepatide
Larger HOMA-IR reductions than semaglutide in head-to-head trials, attributed to both larger weight-loss magnitude and a possible direct GIP-mediated insulin-sensitizing effect. The GIP receptor's role in insulin sensitivity is still being characterized; preclinical data suggests both insulin-sensitizing and adipose-targeting effects beyond simple weight loss.
Retatrutide
Triple agonist with weight-loss numbers exceeding tirzepatide in Phase 2. The glucagon component adds direct hepatic effects on glucose handling. Phase 3 will clarify whether the insulin-sensitizing effect exceeds tirzepatide's at equivalent weight loss.
Supporting cast
MOTS-c
Mitochondrial-derived peptide that activates AMPK and improves insulin sensitivity in rodent metabolic-disease models. Plasma MOTS-c declines with age and inversely correlates with insulin resistance in human cross-sectional data. Synthetic MOTS-c analog (MB-4343) cleared a Phase 1 safety study without dose-limiting toxicity. Human efficacy data in insulin resistance specifically is still in development.
5-Amino-1MQ
NNMT inhibitor with adipose-specific effects in animal studies. NNMT inhibition improves insulin sensitivity in preclinical models. Zero human insulin-resistance trials — the case is mechanistic, not validated.
What the evidence does not support
- Claims that BPC-157, GHK-Cu, or any tissue-repair peptide improves insulin sensitivity
- Claims that GH secretagogues (CJC-1295, ipamorelin, MK-677) improve insulin sensitivity — these typically decrease insulin sensitivity by elevating IGF-1
- Use as a substitute for first-line interventions (metformin, weight loss, exercise)
Where to source
For prediabetic and metabolic-syndrome patients seeking peptide therapy, GLP-1 access has tightened with the end of the FDA-declared shortage. Branded products are preferred where insurance allows; research-use vendor data is in our rankings.
What we don't know
- Whether early-stage insulin resistance (HOMA-IR 2.0–3.5) responds as well to incretin therapy as overt prediabetes/diabetes
- Optimal duration and discontinuation strategies
- Whether MOTS-c monotherapy will be clinically meaningful versus a research curiosity
- Interaction effects with metformin, SGLT2 inhibitors, and pioglitazone in insulin-resistance management
Methodology
Read the full methodology for our scoring rubric.
This page is educational. Insulin-resistance management is a clinical decision involving labs, imaging where indicated, and ongoing monitoring.